Cell Source, Inc. announced that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | 0.00% | -99.83% |
03-22 | Cell Source, Inc. announced that it has received $4.76017 million in funding | CI |
2023 | Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+9.70% | 115B | |
+11.93% | 106B | |
-2.88% | 21.96B | |
-13.85% | 21.87B | |
-5.29% | 19.21B | |
-3.32% | 18.08B | |
-38.57% | 17.71B | |
+6.28% | 14.32B | |
+33.66% | 12.42B |
- Stock Market
- Equities
- CLCS Stock
- News Cell Source, Inc.
- Cell Source, Inc. Appoints Terry Strom as Chairman of Scientific Advisory Board